Gyre Therapeutics (GYRE) Goodwill & Intangibles (2010 - 2026)
Gyre Therapeutics (GYRE) reported Goodwill & Intangibles of $5.8 million for Q1 2026, up 4.75% year-over-year from $5.6 million in Q1 2025, and up 1.62% on a QoQ basis from $5.8 million in Q4 2025.
Gyre Therapeutics (GYRE) has 10 years of Goodwill & Intangibles data on file, last reported at $5.8 million in Q1 2026.
- Quarterly Goodwill & Intangibles rose 4.75% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (up 4.75% YoY) and the FY2025 annual result came in at $5.8 million, up 2006.23% from the prior year.
- Goodwill & Intangibles climbed to $5.8 million in Q1 2026 per GYRE's latest filing, from $5.8 million in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $5.8 million in Q1 2026 and bottomed at $273000.0 in Q4 2023.
- The 5-year median for Goodwill & Intangibles is $611000.0 (2024), against an average of $2.8 million.
- The widest annual swing landed in 2023, when Goodwill & Intangibles decreased 8.08%; it then surged 2006.23% in 2025.
- Tracing GYRE's Goodwill & Intangibles over 5 years: stood at $297000.0 in 2022, then fell by 8.08% to $273000.0 in 2023, then changed by 0.0% to $273000.0 in 2024, then surged by 2006.23% to $5.8 million in 2025, then increased by 1.62% to $5.8 million in 2026.
- Per Business Quant, the three latest GYRE Goodwill & Intangibles figures stand at $5.8 million (Q1 2026), $5.8 million (Q4 2025), and $5.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.84 Mn |
| Dec 31, 2025 | 5.75 Mn |
| Sep 30, 2025 | 5.69 Mn |
| Jun 30, 2025 | 5.63 Mn |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | 273,000.00 |
| Sep 30, 2024 | 611,000.00 |
| Jun 30, 2024 | 598,000.00 |
| Mar 31, 2024 | 601,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Dec 31, 2022 | 297,000.00 |
| Dec 31, 2014 | 296,000.00 |
| Jun 30, 2014 | 89,000.00 |
| Mar 31, 2014 | 93,000.00 |
| Dec 31, 2013 | 97,000.00 |
| Sep 30, 2013 | 102,000.00 |
| Jun 30, 2013 | 106,000.00 |
| Mar 31, 2013 | 110,000.00 |
| Dec 31, 2012 | 296,000.00 |
| Sep 30, 2012 | 119,000.00 |
| Jun 30, 2012 | 123,000.00 |
| Mar 31, 2012 | 128,000.00 |
| Dec 31, 2011 | 296,000.00 |
| Sep 30, 2011 | 136,000.00 |
| Jun 30, 2011 | 141,000.00 |
| Dec 31, 2010 | 149,000.00 |